Bioequivalence Study in Healthy Subjects
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Candesartan cilexetil
Candesartan cilexetil
Sponsored by

About this trial
This is an interventional basic science trial for Hypertension focused on measuring Candesartan, Bioequivalence
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Body mass index (BMI) 19-27 kg/m2 calculated from height and weight at the Screening visit
- Clinically normal physical findings including ECG and safety laboratory values at the Screening visit and on Day -1 of each treatment period, including negative results for drugs-of-abuse, alcohol, Hepatitis B, Hepatitis C and HIV.
Exclusion Criteria:
- History of significant mental, cardiac, renal, hepatic or significant gastrointestinal disease (that may affect the rate and extent of absorption of the IP), as judged by the Investigator
- Any condition which could modify the absorption of the IPs
- Previous randomisation of treatment in the present study
- History or symptoms and signs of ongoing severe allergic disease/hypersensitivity
Sites / Locations
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
A
B
Arm Description
Candesartan cilexetil 1mg/mL
Candesartan cilexetil 1.6mg/mL
Outcomes
Primary Outcome Measures
PK (Candesartan cilexetil)
Secondary Outcome Measures
Safety variables (adverse events, ECG, vital signs, safety laboratory)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00844324
Brief Title
Bioequivalence Study in Healthy Subjects
Official Title
A Single Dose, 2-Period, Cross-over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil
Study Type
Interventional
2. Study Status
Record Verification Date
December 2010
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed as a Phase-I, 2-period, cross-over, randomised, open-label, single centre study to determine bioequivalence of a single 32 mg dose of the proposed commercial oral suspension of candesartan cilexetil (1 mg/mL) and a single 32 mg dose of the candesartan cilexetil oral suspension (1.6 mg/mL) used in the paediatric program.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Candesartan, Bioequivalence
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
Candesartan cilexetil 1mg/mL
Arm Title
B
Arm Type
Experimental
Arm Description
Candesartan cilexetil 1.6mg/mL
Intervention Type
Drug
Intervention Name(s)
Candesartan cilexetil
Intervention Description
Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
Intervention Type
Drug
Intervention Name(s)
Candesartan cilexetil
Intervention Description
Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
Primary Outcome Measure Information:
Title
PK (Candesartan cilexetil)
Time Frame
Collected at pre-dose and at selected time points; 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30 and 36 hours post-dose
Secondary Outcome Measure Information:
Title
Safety variables (adverse events, ECG, vital signs, safety laboratory)
Time Frame
During the whole treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Provision of informed consent prior to any study specific procedures
Body mass index (BMI) 19-27 kg/m2 calculated from height and weight at the Screening visit
Clinically normal physical findings including ECG and safety laboratory values at the Screening visit and on Day -1 of each treatment period, including negative results for drugs-of-abuse, alcohol, Hepatitis B, Hepatitis C and HIV.
Exclusion Criteria:
History of significant mental, cardiac, renal, hepatic or significant gastrointestinal disease (that may affect the rate and extent of absorption of the IP), as judged by the Investigator
Any condition which could modify the absorption of the IPs
Previous randomisation of treatment in the present study
History or symptoms and signs of ongoing severe allergic disease/hypersensitivity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Hainer, MD
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Klaus Francke, Dr
Organizational Affiliation
Parexel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Harrow
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Bioequivalence Study in Healthy Subjects
We'll reach out to this number within 24 hrs